CG Oncology Stock (NASDAQ:CGON)
Previous Close
$26.10
52W Range
$14.80 - $40.47
50D Avg
$26.21
200D Avg
$28.46
Market Cap
$1.97B
Avg Vol (3M)
$1.09M
Beta
0.87
Div Yield
-
CGON Company Profile
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.